Program
SYH2062
A development code. Also written as “SYH2062 injection”.
Its studies are mostly in Essential Hypertension, led by CSPC Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 22 open or running | phase 2since Jul 30, 2026 | Feb 19, 2025 | Jan 31, 2027phase 2 · NCT07940075 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 19, 2025First study: phase 1 study in Healthy Chinese VolunteersFirst studyNCT06842537 · 46 planned · China
- Jul 30, 2026Phase 2 study in Mild to Moderate Primary HypertensionPhase 2 reachedNCT07940075 · 360 planned · China
Ahead
- Jan 31, 2027Primary completion: phase 2 study in Mild to Moderate Primary HypertensionNCT07940075
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07940075Mild to Moderate Primary Hypertension · China | 2 | Recruiting | Jan 31, 2027 | 360 |
| NCT06842537Healthy Chinese Volunteers · China | 1 | Recruiting | Dec 31, 2025 | 46 |
How it is read
Names in the registry
- “SYH2062”, 1 entry
- “SYH2062 injection”, 1 entry
Codes read as this program: SYH2062.
Conditions, from the studies’ own filings
- Essential Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.